Previous in vitro studies of PI3K inhibitors in prostate cancer, colon cancer and breast cancer cell lines have suggested a reduced PCho concentration and an increased GPC concentration, whereas in vivo studies in glioblastoma xenografts have suggested a decrease in tCho [40,62,63]. Here, PIK3CA is linked to Familial prostate cancer.